Advertisement
U.S. markets open in 5 hours 21 minutes
  • S&P Futures

    5,107.75
    +4.00 (+0.08%)
     
  • Dow Futures

    39,020.00
    -23.00 (-0.06%)
     
  • Nasdaq Futures

    18,124.00
    +41.25 (+0.23%)
     
  • Russell 2000 Futures

    2,057.60
    +0.30 (+0.01%)
     
  • Crude Oil

    78.32
    +0.06 (+0.08%)
     
  • Gold

    2,047.80
    -6.90 (-0.34%)
     
  • Silver

    22.73
    -0.16 (-0.70%)
     
  • EUR/USD

    1.0814
    +0.0007 (+0.06%)
     
  • 10-Yr Bond

    4.2520
    0.0000 (0.00%)
     
  • Vix

    13.27
    -0.13 (-0.97%)
     
  • GBP/USD

    1.2632
    +0.0006 (+0.05%)
     
  • USD/JPY

    150.5440
    +0.5600 (+0.37%)
     
  • Bitcoin USD

    62,127.46
    -792.61 (-1.26%)
     
  • CMC Crypto 200

    885.54
    0.00 (0.00%)
     
  • FTSE 100

    7,666.06
    +36.04 (+0.47%)
     
  • Nikkei 225

    39,910.82
    +744.63 (+1.90%)
     

LFMD, FUV & ACAD Reminders: Bronstein, Gewirtz & Grossman LLC Reminds Shareholders of Class Actions and Encourages Investors to Contact the Firm

NEW YORK, NY / ACCESSWIRE / May 4, 2021 / Bronstein, Gewirtz & Grossman, LLC reminds investors that a class action lawsuit has been filed against the following publicly-traded companies. You can review a copy of the Complaints by visiting the links below or you may contact Peretz Bronstein, Esq. or his Investor Relations Analyst, Yael Hurwitz of Bronstein, Gewirtz & Grossman, LLC at 212-697-6484. If you suffered a loss, you can request that the Court appoint you as lead plaintiff. Your ability to share in any recovery doesn't require that you serve as a lead plaintiff. A lead plaintiff acts on behalf of all other class members in directing the litigation. The lead plaintiff can select a law firm of its choice. An investor's ability to share in any potential future recovery is not dependent upon serving as lead plaintiff.

LifeMD, Inc. (NASDAQ:LFMD)
Class Period:
January 19, 2021 - April 13, 2021
Deadline: June 15, 2021|
For more info:
www.bgandg.com/lfmd.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) many of LifeMD's executives were associated with Redwood Scientific when it was charged for unlawful autoshipping, abusive telemarketing, and false claims, and that they employed similar practices at the Company; (2) LifeMD engaged in autoshipping products to unwilling customers to record recurring revenue and the Company made it difficult to cancel such subscriptions; (3) certain of the purportedly licensed physicians on the Company's platform were not in fact licensed and faced disciplinary action; (4) as a result of the foregoing practices, the Company was reasonably likely to face regulatory scrutiny and/or reputational harm; and (5) as a result of the foregoing, Defendants' positive statements about the Company's business, operations, and prospects were materially misleading and/or lacked a reasonable basis.

Arcimoto, Inc. (NASDAQ:FUV)
Class Period:
February 14, 2018 - March 22, 2021
Deadline: June 18, 2021
For more info: www.bgandg.com/fuv.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the preorders of Arcimoto's Fun Utility Vehicles ("FUVs") were fabricated or never completed, with only 19 units delivered out of an alleged preorder of 422; (2) Arcimoto failed to disclose to customers that nearly 100% of its vehicles delivered were under safety recall; (3) Arcimoto's largest customer, R-Key-Moto, was an undisclosed related party owned by insider FOD Capital, LLC; (4) Arcimoto's partnership with HULA was an undisclosed related party transaction; and (5) as a result, defendants' public statements were materially false and/or misleading at all relevant times.

ACADIA Pharmaceuticals Inc. (NASDAQ:ACAD)
Class Period:
June 15, 2020 - April 4, 2021
Deadline: June 18, 2021
For more info: www.bgandg.com/acad.

The complaint alleges that throughout the Class Period, Defendants made materially false and/or misleading statements and failed to disclose that: (1) the materials submitted in support of the pimavanserin sNDA contained statistical and design deficiencies; (2) accordingly, the pimavanserin sNDA lacked the evidentiary support that the Company had led investors to believe it possessed; (3) the FDA was unlikely to approve the pimavanserin sNDA in its present form; and (4) as a result, the Company's public statements were materially false and misleading at all relevant times.

Contact:

Bronstein, Gewirtz & Grossman, LLC
Peretz Bronstein or Yael Hurwitz
212-697-6484 | info@bgandg.com

SOURCE: Bronstein, Gewirtz and Grossman, LLC



View source version on accesswire.com:
https://www.accesswire.com/643740/LFMD-FUV-ACAD-Reminders-Bronstein-Gewirtz-Grossman-LLC-Reminds-Shareholders-of-Class-Actions-and-Encourages-Investors-to-Contact-the-Firm

Advertisement